...会期刊-中国医师协会期刊-医学外文文献 lide,PG)、普拉克索(pramipexole, PP)、罗匹尼罗(ropinirole,RR)和卡麦角林(cabergoline, CG).每次试验时,遵医嘱首先用1种DAA治疗的患者,诸如药效减退和异动症之类的并发症都显著减少.
基于4个网页-相关网页
目的：使用麦角衍生的多巴胺激动剂，已经证实帕金森病人使用培高利特和卡麦角林可能增加瓣膜心脏病。
Objective: Treatment with ergot-derived dopamine agonists, pergolide, and cabergoline has been associated with an increased frequency of valvular heart disease in Parkinson's disease.
卡麦角林的累积剂量和轻度、中度、重度瓣膜返流无明显相关。
There was no relation between the cumulative dose of cabergoline and the presence of mild, moderate, or severe valve regurgitation.
应用推荐